



HU000030901T2

(19) **HU**(11) Lajstromszám: **E 030 901**(13) **T2****MAGYARORSZÁG**
Szellemi Tulajdon Nemzeti Hivatala**EURÓPAI SZABADALOM**
SZÖVEGÉNEK FORDÍTÁSA(21) Magyar ügyszám: **E 12 844650**
(22) A bejelentés napja: **2012. 12. 05.**(51) Int. Cl.: **C07D401/12** (2006.01)
A61K 31/445 (2006.01)
A61P 25/00 (2006.01)
C07D211/46 (2006.01)(96) Az európai bejelentés bejelentési száma:
EP 20120844650(97) Az európai bejelentés közzétételi adatai:
EP 2888243 A1 **2014. 02. 27.**(86) A nemzetközi (PCT) bejelentési szám:
PCT/IN 12/000796(97) Az európai szabadalom megadásának meghirdetési adatai:
EP 2888243 B1 **2016. 08. 17.**(87) A nemzetközi közzétételi szám:
WO 14030170(30) Elsőbbségi adatok:
CH34642012 **2012. 08. 23.** **IN**
(72) Feltaláló(k):
NIROGI, Ramakrishna, Hyderabad 500 034Andhra Pradesh (IN)
SHINDE, Anil, Karbhari, Hyderabad 500 034Andhra Pradesh (IN)
DWARAMPUDI, Adi, Reddy, Hyderabad 500 034Andhra Pradesh (IN)
JASTI, Venkateswarlu, Hyderabad 500 034Andhra Pradesh (IN)(73) Jogosult(ak):
Suven Life Sciences Limited, Hyderabad 500 034, Andra Pradesh (IN)(74) Képviselő:
Arinova Szabadalmi és Védjegy Iroda, Budapest(54) **Akrlamid vegyületek mint hisztamin H3-receptor ligandumok**

Az európai szabadalom ellen, megadásának az Európai Szabadalmi Közlönyben való meghirdetésétől számított kilenc hónapon belül, felszólalást lehet benyújtani az Európai Szabadalmi Hivatalnál. (Európai Szabadalmi Egyezmény 99. cikk(1))

A fordítást a szabadalmas az 1995. évi XXXIII. törvény 84/H. §-a szerint nyújtotta be. A fordítás tartalmi helyességét a Szellemi Tulajdon Nemzeti Hivatala nem vizsgálta.



(11) **EP 2 888 243 B1**

(12) **EUROPEAN PATENT SPECIFICATION**

(45) Date of publication and mention
of the grant of the patent:
17.08.2016 Bulletin 2016/33

(51) Int Cl.:
C07D 401/12 ^(2006.01) **C07D 211/46** ^(2006.01)
A61K 31/445 ^(2006.01) **A61P 25/00** ^(2006.01)

(21) Application number: **12844650.7**

(86) International application number:
PCT/IN2012/000796

(22) Date of filing: **05.12.2012**

(87) International publication number:
WO 2014/030170 (27.02.2014 Gazette 2014/09)

(54) **ACRYLAMIDE COMPOUNDS AS HISTAMINE H3 RECEPTOR LIGANDS**

ACRYLAMIDVERBINDUNGEN ALS HISTAMIN-H3-REZEPTORLIGANDEN

COMPOSÉS ACRYLAMIDES UTILISÉS COMME LIGANDS DES RÉCEPTEURS H3 À L'HISTAMINE

(84) Designated Contracting States:
**AL AT BE BG CH CY CZ DE DK EE ES FI FR GB
GR HR HU IE IS IT LI LT LU LV MC MK MT NL NO
PL PT RO RS SE SI SK SM TR**
Designated Extension States:
BA ME

(30) Priority: **23.08.2012 IN CH34642012**

(43) Date of publication of application:
01.07.2015 Bulletin 2015/27

(73) Proprietor: **Suven Life Sciences Limited**
Hyderabad 500 034, Andhra Pradesh (IN)

(72) Inventors:
• **NIROGI, Ramakrishna**
Hyderabad 500 034
Andhra Pradesh (IN)

- **SHINDE, Anil, Karbhari**
Hyderabad 500 034
Andhra Pradesh (IN)
- **DWARAMPUDI, Adi, Reddy**
Hyderabad 500 034
Andhra Pradesh (IN)
- **JASTI, Venkateswarlu**
Hyderabad 500 034
Andhra Pradesh (IN)


(74) Representative: **HGF Limited**
1 City Walk
Leeds LS11 9DX (GB)

(56) References cited:
EP-B1- 1 761 519 WO-A1-2005/117865
WO-A1-2009/013195

Note: Within nine months of the publication of the mention of the grant of the European patent in the European Patent Bulletin, any person may give notice to the European Patent Office of opposition to that patent, in accordance with the Implementing Regulations. Notice of opposition shall not be deemed to have been filed until the opposition fee has been paid. (Art. 99(1) European Patent Convention).

Description**Field of Invention**

[0001] The present invention relates to novel acrylamide compounds of formula (I) and their pharmaceutically acceptable salts, for treatment of various disorders that are related to Histamine H₃ receptors.

**Background of the Invention**


[0002] Histamine H₃ receptor is a G-protein coupled receptor (GPCR) and one out of the four receptors of Histamine family. Histamine H₃ receptor is identified in 1983 and its cloning and characterization were done in 1999. Histamine H₃ receptor is expressed to a larger extent in central nervous system and lesser extent in the peripheral nervous system.

[0003] Literature evidence suggests that Histamine H₃ receptor ligands can be used in treatment of cognitive disorders (British Journal of Pharmacology, 2008, 154(6), 1166-1181), dementia (Drug News Perspective, 2010, 23(2), 99-103), attention deficit hyperactivity disorder, obesity (Indian Journal of Pharmacology, 2001, 33, 17-28), schizophrenia (Biochemical Pharmacology, 2007, 73(8), 1215-1224) and pain (Journal of Pharmacology and Experimental Therapeutics, 2011, 336(1), 30-37).

[0004] Patent publications WO 2007/137955, US 2009/0170869, US 2010/0029608, US 2010/0048580, WO 2009/100120, WO 2009/121812 and WO 2009/135842 disclosed series of compounds as ligands at Histamine H₃ receptors. While some Histamine H₃ receptor ligands have been disclosed, no compound till date is launched in market in this area of research, and there still exists a need and scope to discover new drugs with novel chemical structures for treatment of disorders affected by Histamine H₃ receptors.

Summary of the Invention

[0005] The present invention relates to novel acrylamide Histamine H₃ receptor ligands of the formula (I),




wherein,

at each occurrence, R₁ is independently selected from hydrogen, halogen, alkyl or alkoxy;

"A" is alkyl, cycloalkyl or cycloalkylalkyl; "X" is C or N;

"Y" is C, O or



or its pharmaceutically acceptable salts.

[0006] The present invention relates to use of a therapeutically effective amount of compound of formula (I), to manufacture a medicament in the treatment of various disorders that are related to Histamine H₃ receptors.

[0007] Specifically, the compounds of this invention are useful in the treatment of various disorders such as cognitive deficits in schizophrenia, narcolepsy, obesity, attention deficit hyperactivity disorder, pain or alzheimer's disease.

[0008] In another aspect, the invention relates to pharmaceutical compositions containing a therapeutically effective amount of at least one compound of formula (I), or its their pharmaceutically acceptable salts thereof, in admixture with pharmaceutically acceptable excipient.

[0009] In still another aspect, the invention further relates to the process for preparing compounds of formula (I) and their pharmaceutically acceptable salts.

[0010] Representative compounds of the present invention include those specified below and their pharmaceutically acceptable salts. The present invention should not be construed to be limited to them.

3-[4-(1-Cyclobutyl piperidin-4-yloxy) phenyl]-1-(morpholin-4-yl) prop-2-ene-1-one fumarate salt;
 3-[4-(1-Cyclobutyl piperidin-4-yloxy) phenyl]-1-(piperidin-1-yl) prop-2-ene-1-one hydrochloride salt;
 3-[4-(1-Cyclobutyl piperidin-4-yloxy) phenyl]-1-(1,1-dioxo thiomorpholin-4-yl) prop-2-ene-1-one hydrochloride salt;
 3-[2-(1-Cyclobutyl piperidin-4-yloxy) pyridin-5-yl]-1-(piperidin-1-yl) prop-2-ene-1-one L(+)-Tartarate salt;
 3-[2-(1-Cyclobutyl piperidin-4-yloxy) pyridin-5-yl]-1-(morpholin-4-yl) prop-2-ene-1-one L(+)-Tartarate salt;
 3-[2-Fluoro-4-(1-isopropyl piperidin-4-yloxy) phenyl]-1-(morpholin-4-yl) prop-2-ene-1-one L(+)-Tartarate salt;
 3-[2-Fluoro-4-(1-cyclobutyl piperidin-4-yloxy) phenyl]-1-(morpholin-4-yl) prop-2-ene-1-one L(+)-Tartarate salt;
 3-[4-(1-Cyclobutyl piperidin-4-yloxy)-2-methyl phenyl]-1-(morpholin-4-yl) prop-2-ene-1-one L(+)-Tartarate salt;
 3-[4-(1-Isopropyl piperidin-4-yloxy)-2-methyl phenyl]-1-(morpholin-4-yl) prop-2-ene-1-one L(+)-Tartarate salt;
 3-[4-(1-Cyclobutyl piperidin-4-yloxy) phenyl]-1-(morpholin-4-yl) prop-2-ene-1-one L(+)-Tartarate salt;
 3-[4-(1-Cyclobutyl piperidin-4-yloxy)-3-methoxy phenyl]-1-(morpholin-4-yl) prop-2-ene-1-one L(+)-Tartarate salt;
 3-[4-(1-Cyclopropylmethyl piperidin-4-yloxy)-3-methoxy phenyl]-1-(morpholin-4-yl) prop-2-ene-1-one L(+)-Tartarate salt;
 3-[4-(1-Isobutyl piperidin-4-yloxy)-3-methoxy phenyl]-1-(morpholin-4-yl) prop-2-ene-1-one L(+)-Tartarate salt;
 3-[4-(1-Isopropyl piperidin-4-yloxy)-3-methoxy phenyl]-1-(morpholin-4-yl) prop-2-ene-1-one L(+)-Tartarate salt;
 3-[4-(1-Isopropyl piperidin-4-yloxy)-3-methoxy phenyl]-1-(piperidin-1-yl) prop-2-ene-1-one L(+)-Tartarate salt;
 3-[4-(1-Cyclobutyl piperidin-4-yloxy)-3-methoxy phenyl]-1-(piperidin-1-yl) prop-2-ene-1-one L(+)-Tartarate salt;
 3-[4-(1-Cyclopropylmethyl piperidin-4-yloxy) phenyl]-1-(morpholin-4-yl) prop-2-ene-1-one;
 3-[4-(1-Isobutyl piperidin-4-yloxy) phenyl]-1-(morpholin-4-yl) prop-2-ene-1-one;
 3-[3-Bromo-4-(1-isopropyl piperidin-4-yloxy) phenyl]-1-(morpholin-4-yl) prop-2-ene-1-one;
 3-[3-Bromo-4-(1-cyclobutyl piperidin-4-yloxy) phenyl]-1-(morpholin-4-yl) prop-2-ene-1-one;
 3-[3-Bromo-4-(1-isobutyl piperidin-4-yloxy) phenyl]-1-(morpholin-4-yl) prop-2-ene-1-one;
 3-[3-Bromo-4-(1-cyclopropylmethyl piperidin-4-yloxy) phenyl]-1-(morpholin-4-yl) prop-2-ene-1-one;
 3-[6-(1-Cyclopropylmethyl piperidin-4-yloxy) pyridin-3-yl]-1-(morpholin-4-yl) prop-2-ene-1-one L(+)-Tartarate salt;
 3-[6-(1-Isobutyl piperidin-4-yloxy) pyridin-3-yl]-1-(morpholin-4-yl) prop-2-ene-1-one L(+)-Tartarate salt;
 3-[2-Chloro-4-(1-cyclobutyl piperidin-4-yloxy) phenyl]-1-(morpholin-4-yl) prop-2-ene-1-one;
 3-[2-Chloro-4-(1-isopropyl piperidin-4-yloxy) phenyl]-1-(morpholin-4-yl) prop-2-ene-1-one;
 3-[2-Chloro-4-(1-cyclopropylmethyl piperidin-4-yloxy) phenyl]-1-(morpholin-4-yl) prop-2-ene-1-one; or
 3-[2-Chloro-4-(1-isobutyl piperidin-4-yloxy) phenyl]-1-(morpholin-4-yl) prop-2-ene-1-one.

Detailed Description of the Invention

[0011] Unless otherwise stated, the following terms used in the specification and claims have the meanings given below:

The term "halogen" means fluorine, chlorine, bromine or iodine.

[0012] The term "alkyl" means straight chain or branched hydrocarbon radical consisting solely of carbon and hydrogen atoms, containing no unsaturation, having from one to eight carbon atoms, and which is attached to the rest of the molecule by a single bond. Exemplary "alkyl" groups include methyl, ethyl, n-propyl, iso-propyl and the like.

[0013] The term "alkoxy" means an alkyl group attached via an oxygen linkage to the rest of the molecule. Exemplary "alkoxy" groups include methoxy, ethoxy, propyloxy, iso-propyloxy and the like.

[0014] The term "cycloalkyl" means non-aromatic mono cyclic ring of 3 to 8 carbon atoms.

[0015] Exemplary "cycloalkyl" groups include cyclopropyl, cyclobutyl, cyclopentyl and the like.

[0016] The term "cycloalkylalkyl" means non-aromatic mono cyclic ring of 3 to 8 carbon atoms attached to an alkyl group. Exemplary "cycloalkylalkyl" groups include cyclopropyl methyl, cyclobutyl methyl, cyclopentyl methyl and the like.

[0017] The phrase "pharmaceutically acceptable salts" indicates that the substance or composition must be compatible chemically and/or toxicologically, with the other ingredients comprising a formulation, the mammal being treated therewith.

[0018] The phrase "therapeutically effective amount" is defined as an amount of a compound of the present invention that (i) treats the particular disease, condition or disorder (ii) eliminates one or more symptoms of the particular disease, condition or disorder (iii) delays the onset of one or more symptoms of the particular disease, condition or disorder

described herein.

[0019] Commercial reagents were utilized without further purification. Room temperature refers to 25 - 40 °C. Unless otherwise stated, all mass spectra were carried out using ESI conditions. ¹H-NMR spectra were recorded at 400 MHz on a Bruker instrument. Deuterated chloroform, methanol or dimethylsulfoxide was used as solvent. TMS was used as internal reference standard. Chemical shift values are expressed in parts per million (δ) values. The following abbreviations are used for the multiplicity for the NMR signals: s=singlet, bs=broad singlet, d=doublet, t=triplet, q=quartet, qui=quintet, h=heptet, dd=double doublet, dt=double triplet, tt=triplet of triplets, m=multiplet. Chromatography refers to column chromatography performed using 100 - 200 mesh silica gel and executed under nitrogen pressure (flash chromatography) conditions.

Pharmaceutical compositions


[0020] In order to use the compounds of formula (I) in therapy, they will normally be formulated into a pharmaceutical composition in accordance with standard pharmaceutical practice.

[0021] The pharmaceutical compositions of the present invention may be formulated in a conventional manner using one or more pharmaceutically acceptable excipient. The pharmaceutically acceptable excipient is carrier or diluent. Thus, the active compounds of the invention may be formulated for oral, intranasal or parenteral (e.g., intravenous, intramuscular or subcutaneous). Such pharmaceutical compositions and processes for preparing same are well known in the art (The Science and Practice of Pharmacy, D.B. Troy, 21st Edition, Williams & Wilkins, 2006).

[0022] The dose of the active compounds can vary depending on factors such as the route of administration, age and weight of patient, nature and severity of the disease to be treated and similar factors. Therefore, any reference herein to a pharmacologically effective amount of the compounds of general formula (I) refers to the aforementioned factors

Methods of Preparation

[0023] The compounds of formula (I) can be prepared by Scheme I as shown below.



Scheme I

[0024] Reductive amination of the compound of formula (1) with compound of formula (2) to form compound of formula (I). This reaction is preferably carried out in solvent such as tetrahydrofuran, toluene, ethyl acetate, dichloromethane, dimethylformamide, and the like or a mixture thereof and preferably by using dichloromethane. The reaction may be affected in the presence of a reducing agent such as diisobutylaluminum hydride, sodium triacetoxyborohydride, dimethylsulfide borane, sodium bis(2-methoxyethoxy)aluminumhydride, sodium hydrosulfite, sodium borohydride, sodium cyanoborohydride and sodium dithionite and preferably by using sodium triacetoxyborohydride. The reaction is carried out at room temperature. The duration of the reaction may range from 4 hours to 8 hours, preferably from a period of 5 hours to 7 hours.

[0025] Compounds of formula (I) can be prepared by using preparations 1 & 2 or can be prepared by using conventional methods or by modifications using known process.

[0026] Compounds of formula (2) may be commercially available or can be prepared by conventional methods or by modification using known process.

[0027] The pharmaceutically acceptable salts forming a part of this invention may be prepared by treating the compound of formula (I) with 1-6 equivalents of acids such as hydrochloric, hydrobromic, sulfuric, nitric, phosphoric acid, succinic, maleic, acetic, fumaric, citric, malic, tartaric, benzoic, p-toluic, p-toluenesulfonic, methanesulfonic or naphthalenesulfonic acid. The most preferable salts of compounds of formula (I) are fumarate, L(+)-tartarate, hydrochloride, oxalate and sulfate.

Examples

[0028] The novel compounds of the present invention were prepared according to the following experimental procedures, using appropriate materials and appropriate conditions.

Preparation 1: Preparation of 3-[4-(Piperidin-4-yloxy) phenyl]-1-(morpholin-4-yl) prop-2-ene-1-one

Step (i): Preparation of t-Butyl 4-(4-formyl phenoxy) piperidine-1-carboxylate

[0029] A solution of 4-Hydroxybenzaldehyde (20.1 grams, 0.164 moles), potassium carbonate (67.9 grams, 0.492 moles) and t-butyl 4-(toluene-4-sulfonyloxy) piperidine-1-carboxylate (70 grams, 0.197 moles) in acetonitrile (1000 mL) was stirred for 18 hours at 80 °C. The progress of the reaction was monitored by thin layer chromatography. After completion of reaction, the mass was cooled to room temperature and quenched on to chilled water (1000 mL). The compound was extracted with dichloromethane (3 x 500 mL). The resulting dichloromethane layer was washed with 10 % lye solution (100 mL), water (100 mL) and brine solution (100 mL). The organic phase was dried over sodium sulfate and concentrated under reduced pressure to afford the title compound (50.3 grams).

Yield: 100 %.

¹H - NMR (δ ppm): 1.48 (9H, s), 1.76 - 1.83 (2H, m), 1.96 - 2.04 (2H, m), 3.36 - 3.41 (2H, m), 3.68 - 3.73 (2H, m), 4.45 - 4.60 (1H, m), 6.96 - 7.02 (2H, m), 7.78 - 7.85 (2H, m), 9.89 (1H, s); Mass (m/z): 306.4 (M+H)⁺.

Step (ii): Preparation of 3-[4-(1-t-Butyloxycarbonyl piperidin-4-yloxy) phenyl] prop-2-ene-1-oic acid

[0030] A solution of t-Butyl 4-(4-formyl phenoxy) piperidine-1-carboxylate (50.2 grams, 0.164 moles, obtained in above step), malonic acid (50.6 grams, 0.486 moles) and piperidine (12.5 mL) in pyridine (250 mL) was stirred for 8 hours at 110 °C under nitrogen atmosphere.

[0031] The progress of the reaction was monitored by thin layer chromatography. After completion of reaction, the mass was concentrated and the resulting slurry was triturated with n-hexane (200 mL) and stirred for 30 minutes. The solids, thus obtained, were washed with n-hexane (100 mL) and dried under vacuum to afford the title compound (39.1 grams).

Yield: 68 %.

¹H - NMR (δ ppm): 1.47 (9H, s), 1.76 - 1.80 (2H, m), 1.90 - 1.96 (2H, m), 3.35 - 3.40 (2H, m), 3.67 - 3.72 (2H, m), 4.53 - 4.60 (1H, m), 6.30 - 6.34 (1H, d, J = 15.32 Hz), 6.89 - 6.95 (2H, d, J = 8.64); 7.47 - 7.53 (2H, d, J = 8.64 Hz), 7.71 - 7.75 (1H, d, J = 15.33 Hz);

Mass (m/z): 348.2 (M+H)⁺.

Step (iii): Preparation of 3-[4-(1-t-Butyloxycarbonyl piperidin-4-yloxy) phenyl]-1-(morpholin-4-yl) prop-2-ene-1-one

[0032] To a stirred solution of 3-[4-(1-t-butyloxycarbonyl piperidin-4-yloxy) phenyl] prop-2-ene-1-oic acid (38 grams, 0.109 moles, obtained in above step) and triethylamine (38.4 mL, 0.273 moles) in dichloromethane (500 mL) was added ethylchloroformate (13.6 mL, 0.142 moles) at 0 °C. The reaction mass was further stirred for 2 hours at 0 - 5 °C. Morpholine (19.2 mL, 0.219 moles) was added to above mass at 0 - 5 °C and the resulting mixture were stirred for 2 hours. The progress of the reaction was monitored by thin layer chromatography. After completion of reaction, the mass was quenched by adding water (100 mL). Layers were separated and the organic layer was washed with brine solution (100 mL) and dried over sodium sulphate. The organic phase was concentrated under vacuum to obtain the crude residue, which was further purified by flash chromatography using methanol:triethylamine:chloroform in the ratio of 1: 1: 98 to afford the title compound (34 grams).

Yield: 74 %.

¹H - NMR (δ ppm): 1.47 (9H, s), 1.76 - 1.81 (2H, m), 1.90 - 1.95 (2H, m), 3.32 - 3.39 (2H, m), 3.62 - 3.79 (10H, m), 4.49 - 4.55 (1H, m), 6.69 - 6.73 (1H, d, J = 15.92 Hz), 6.88 - 6.94 (2H, d, J = 8.64. Hz); 7.45 - 7.49 (2H, d, J = 8.64 Hz), 7.64

- 7.68 (1H, d, J = 15.92);
Mass (m/z): 417.3 (M+H)⁺.

Step (iv): Preparation of 3-[4-(Piperidin-4-yloxy) phenyl]-1-(morpholin-4-yl) prop-2-ene-1-one

[0033] A solution of 3-[4-(1-t-Butyloxycarbonyl piperidin-4-yloxy) phenyl]-1-(morpholin-4-yl) prop-2-ene-1-one (29.8 grams, 0.071 moles) in dichloromethane (400 mL) was treated with trifluoroacetic acid (55.6 mL, 0.726 moles) at room temperature. The reaction mass was stirred for 6 hours at room temperature. The progress of the reaction was monitored by thin layer chromatography. After completion of the reaction, the reaction mass was poured on to chilled water (500 mL) and basified with 40 % lye solution (pH ~ 9). The layers were separated and the aqueous layer was extracted with dichloromethane (2 x 200 mL) and the combined organic phase was washed with water (150 mL), brine solution (150 mL) and dried over sodium sulphate. The organic phase was concentrated on rotavacuum to afford the title compound (21.2 grams).

Yield: 90 %.

¹H - NMR (δ ppm): 1.63 - 1.72 (2H, m), 2.00 - 2.04 (2H, m), 2.71 - 2.77 (2H, m), 3.12 - 3.18 (2H, m), 3.73 (8H, m), 4.39 - 4.44 (1H, m), 6.69 - 6.73 (1H, d, J = 15.32 Hz), 6.89 - 6.91 (2H, d, J = 8.64 Hz); 7.45 - 7.47 (2H, d, J = 8.64 Hz), 7.64 - 7.68 (1H, d, J = 15.32 Hz);
Mass (m/z): 317.3 (M+H)⁺.

Preparation 2: Preparation of 1-(Morpholin-4-yl)-3-12-(piperidin-4-yloxy) pyridin-5-yl]-prop-2-ene-1-one

Step (i): Preparation of t-Butyl 4-(5-bromo pyridin-2-yloxy) piperidine-1-carboxylate

[0034] To a stirred solution of sodium hydride (4.0 grams, 60 % dispersion in mineral oil, 0.1 moles) in tetrahydrofuran (50 mL) was added t-butyl 4-hydroxy piperidine-1-carboxylate (15 grams, 0.075 moles) in tetrahydrofuran (50 mL) at 10 °C under nitrogen atmosphere. The mass was stirred for 1 hour at room temperature. A solution of 2, 5-dibromo pyridine (11.8 grams, 0.05 moles) in tetrahydrofuran (50 mL) was added drop wise to the above reaction mass at room temperature and stirred for 4 hours at 65 °C. The progress of the reaction was monitored by thin layer chromatography. After completion of reaction, the mass was quenched on to chilled water (600 mL) and the compound was extracted with ethyl acetate (3 x 200 mL). The resulting organic layer was washed with water, dried over sodium sulfate and concentrated under vacuum. The residue, thus obtained, was purified by flash chromatography using ethyl acetate: n-hexane in the ratio of 1:9 to afford the title compound (15 grams).

Yield: 84 %.

¹H - NMR (δ ppm): 1.47 (9H, s), 1.68 - 1.74 (2H, m), 1.91 - 2.00 (2H, m), 3.24 - 3.31 (2H, m), 3.72 - 3.78 (2H, m), 5.14 - 5.18 (1H, m), 6.62 - 6.64 (1H, d, J = 8.78 Hz), 7.62 - 7.65 (1H, dd, J = 8.76 & 2.57 Hz), 8.15 - 8.16 (1H, d, J = 2.48 Hz);
Mass (m/z): 357.1, 359.2 (M+H)⁺.

Step (ii): Preparation of 3-[2-(1-t-Butyloxycarbonyl piperidin-4-yloxy) pyridin-5-yl]-1-(morpholin-4-yl) prop-2-ene-1-one

[0035] A solution of t-butyl 4-(5-bromo pyridin-2-yloxy) piperidine-1-carboxylate (1 gram, 2.80 mmoles), 4-acryloyl-morpholine (0.63 gram, 4.46 mmoles), palladium acetate (13 mg, 0.061 mmoles) tri(o-tolyl) phosphine (25.6 mg, 0.084 mmoles) and potassium carbonate (0.62 g, 4.49 mmoles) in DMF (15 mL) was stirred for 3 hours at 140 °C. The progress of the reaction was monitored by thin layer chromatography. After completion of reaction, the mass was quenched on to chilled water (30 mL) and the product was extracted with ethyl acetate (3 x 15 mL). The resulting organic layer was washed with water, dried over sodium sulfate and concentrated under vacuum. The residue, thus obtained, was purified by flash chromatography using ethyl acetate: n-hexane in the ratio of 1:1 to afford the title compound (1.07 grams).

Yield: 80 %.

¹H - NMR (δ ppm): 1.47 (9H, s), 1.72 - 1.76 (2H, m), 1.98 - 2.03 (2H, m), 3.26 - 3.32 (2H, m), 3.58 - 3.80 (10H, m), 5.23 - 5.27 (1H, m), 6.33 - 6.37 (1H, d, J = 15.96 Hz), 6.72 - 6.76 (1H, m), 7.62 - 7.67 (1H, m), 7.76 - 7.79 (1H, m), 8.24 - 8.25 (1H, m);
Mass (m/z): 418.3 (M+H)⁺.

Step (iii): Preparation of 1-(Morpholin-4-yl)-3-[2-(piperidin-4-yloxy) pyridin-5-yl]-prop-2-ene-1-one

[0036] A solution of 3-[2-(1-t-Butyloxycarbonyl piperidin-4-yloxy) pyridin-5-yl]-1-(morpholin-4-yl) prop-2-ene-1-one (0.7 grams, 0.0016 moles) in dichloromethane (20 mL) was treated with trifluoroacetic acid (1.3 mL, 0.016 moles) at room temperature. The reaction mass was stirred for 6 hours at room temperature. The progress of the reaction was monitored

by thin layer chromatography. After completion of reaction, the reaction mass was poured on to chilled water (30 mL) and basified with 40 % lye solution (pH ~ 9). The layers were separated and the aqueous layer was further extracted with dichloromethane (2 x 20 mL). The combined organic phase was washed with water (30 mL), brine solution (30 mL) and dried over sodium sulphate. The organic phase was concentrated on rotavacuum to afford the title compound (0.48 grams).

Yield: 90 %.

¹H - NMR (δ ppm): 1.72 - 1.76 (2H, m), 1.98 - 2.03 (2H, m), 3.26 - 3.32 (2H, m), 3.58 - 3.80 (10H, m), 5.23 - 5.27 (1H, m), 6.33 - 6.37 (1H, d, J = 15.96 Hz), 6.72 - 6.76 (2H, m), 7.62 - 7.67 (1H, m), 7.76 - 7.79 (1H, m), 8.24 - 8.25 (1H, m); Mass (m/z): 318.3 (M+H)⁺.

Example 1: Preparation of 3-[4-(1-Cyclobutyl piperidin-4-yloxy) phenyl]-1-(morpholin-4-yl) prop-2-ene-1-one fumarate salt

Step (i): Preparation of 3-[4-(1-Cyclobutyl piperidin-4-yloxy) phenyl]-1-(morpholin-4-yl) prop-2-ene-1-one

[0037] Sodium triacetoxyborohydride (38.6 grams, 0.18 moles) was added in a single lot to a well stirred solution of 3-[4-(Piperidin-4-yloxy) phenyl]-1-(morpholin-4-yl) prop-2-ene-1-one (19.1 grams, 0.060 moles, obtained in preparation 1) and cyclobutanone (6.8 mL, 0.09 moles) in dichloroethane (500 mL). The mixture was further stirred at room temperature for 6 hours. The progress of the reaction was monitored by thin layer chromatography. After completion of reaction, the mass was quenched on to water (1000 mL) and basified with 40 % lye solution (pH ~ 9). The layers were separated and the aqueous layer was extracted with dichloromethane (2 x 200 mL). The combined organic layer was washed with brine solution (250 mL), dried over sodium sulfate, concentrated under vacuum and the residual mass was further purified by flash chromatography using methanol: triethylamine:chloroform in the ratio of 1.5: 0.25: 98.25 to obtain the title compound (17.4 grams).

Yield: 77 %.

¹H - NMR (δ ppm): 1.68 - 1.73 (2H, m), 1.80 - 1.95 (4H, m), 1.99 - 2.06 (4H, m), 2.19 - 2.24 (2H, m), 2.55 - 2.62 (2H, m), 2.70 - 2.79 (1H, m), 3.60 - 3.88 (8H, m), 4.29 - 4.35 (1H, m), 6.68 - 6.72 (1H, d), 6.88 - 6.93 (2H, m); 7.44 - 7.49 (2H, m), 7.64 - 7.68 (1H, d); Mass (m/z): 371.1 (M+H)⁺.

Step (ii): Preparation of 3-[4-(1-Cyclobutyl piperidin-4-yloxy) phenyl]-1-(morpholin-4-yl) prop-2-ene-1-one fumarate salt.

[0038] To a stirred solution of 3-[4-(1-Cyclobutyl piperidin-4-yloxy) phenyl]-1-(morpholin-4-yl) prop-2-ene-1-one (23.52 grams, 0.063 moles) in methanol (300 mL) was added a solution of fumaric acid (7.32 grams, 0.063 moles) in 30 mL methanol. The clear mass, thus obtained, was further stirred for 2-3 hours at room temperature. The solvent was evaporated to afford a solid mass. The solid mass was triturated with diethyl ether (3 x 100 mL) and dried under reduced pressure to obtain the title compound (29.54 grams).

Yield: 95 %.

¹H - NMR (δ ppm): 1.60 - 1.65 (2H, m), 1.73 - 1.77 (2H, m), 2.01 - 2.09 (6H, m), 2.49 - 2.52 (2H, m), 2.81 - 2.89 (2H, m), 3.14 - 3.19 (1H, m), 3.50 - 3.70 (8H, m), 4.50 - 4.60 (1H, m), 6.56 (2H, s), 6.97 - 6.99 (2H, d, J = 8.45 Hz), 7.07 - 7.10 (1H, d, J = 15.32 Hz), 7.43 - 7.47 (1H, d, J = 15.27 Hz), 7.63 - 7.65 (2H, d, J = 8.45 Hz); Mass (m/z): 371.3 (M+H)⁺.

Examples 2-28:

[0039] The compounds of Examples 2-28 were prepared by following the procedures as described in Example 1, with some non-critical variations

2.	3-[4-(1-Cyclobutyl piperidin-4-yloxy) phenyl]-1-(piperidin-1-yl) prop-2-ene-1-one hydrochloride salt	¹ H - NMR (δ ppm): 1.60 - 1.74 (8H, m), 1.82 - 1.87 (2H, m), 1.95 - 2.08 (6H, m), 2.29 (2H, bs), 2.64 (2H, bs), 2.78 - 2.82 (1H, m), 3.62 - 3.65 (4H, m), 4.39 (1H, m), 6.75 - 6.79 (1H, d, J = 15.3 Hz), 6.87 - 6.89 (2H, d, J = 8.63 Hz), 7.44 - 7.46 (2H, d, J = 8.63 Hz), 7.58 - 7.62 (1H, d, J = 15.3 Hz); Mass (m/z): 369.3 (M+H) ⁺ .
----	--	---

EP 2 888 243 B1

(continued)

5	3.	3-[4-(1-Cyclobutyl piperidin-4-yloxy) phenyl]-1-(1,1-dioxo thiomorpholin-4-yl) prop-2-ene-1-one hydrochloride salt	¹ H - NMR (δ ppm): 1.66 - 1.97 (6H, m), 2.07 (5H, s), 2.25 (2H, bs), 2.63 (2H, bs), 2.76 - 2.80 (1H, m), 2.86 - 2.89 (1H, m), 3.10 (4H, m), 4.17 (4H, m), 4.40 (1H, bs), 6.69 - 6.73 (1H, d, J = 15.2 Hz), 6.89 - 6.91 (2H, d, J = 8.65 Hz), 7.46 - 7.48 (2H, d, J = 8.66 Hz), 7.69 - 7.73 (1H, d, J = 15.2 Hz); Mass (m/z): 419.2 (M+H) ⁺ .
10	4.	3-[2-(1-Cyclobutyl piperidin-4-yloxy) pyridin-5-yl]-1-(piperidin-1-yl) prop-2-ene-1-one L(+)-Tartarate salt	¹ H - NMR (δ ppm): 1.66 - 1.72 (8H, m), 1.80 - 1.85 (2H, m), 1.95 - 2.03 (6H, m), 2.32 (2H, bs), 2.63 (2H, bs), 2.80 - 2.82 (1H, m), 2.88 (2H, s), 3.60 - 3.63 (4H, m), 3.82 (1H, m), 5.30-5.32 (1H, d, J = 8.36 Hz), 5.55 - 5.59 (1H, d, J = 15.6 Hz), 5.94 - 5.98 (1H, d, J = 15.6 Hz), 6.52 - 6.54 (1H, d, J = 8.32 Hz), 6.75 (1H, s); Mass (m/z): 370.4 (M+H) ⁺ .
15	5.	3-[2-(1-Cyclobutyl piperidin-4-yloxy) pyridin-5-yl]-1-(morpholin-4-yl) prop-2-ene-1-one L(+)-Tartarate salt	¹ H - NMR (δ ppm): 1.68 - 1.75 (2H, m), 1.80 - 1.95 (4H, m), 1.99 - 2.06 (4H, m), 2.19 - 2.24 (2H, m), 2.55 - 2.62 (2H, m), 2.70 - 2.79 (1H, m), 2.87 (2H, s), 3.60 - 3.88 (8H, m), 5.42 (1H, m), 6.93 - 6.99 (1H, m), 7.09 - 7.13 (1H, m), 7.55 - 7.58 (1H, m), 8.08 - 8.10 (1H, m), 8.32 (1H, s);) Mass (m/z): 372.4 (M+H) ⁺ .
20	6.	3-[2-Fluoro-4-(1-isopropyl piperidin-4-yloxy) phenyl]-1-(morpholin-4-yl) prop-2-ene-1-one L(+)-Tartarate salt	¹ H - NMR (δ ppm): 1.16 - 1.18 (2H, m), 1.20 - 1.27 (1H, m), 1.38 - 1.41 (6H, m), 1.90 - 2.34 (4H, m), 3.30 - 3.69 (4H, m), 3.71 - 3.80 (7H, m), 4.53 (2H, m), 6.80 - 6.89 (2H, m), 7.06 - 7.10 (1H, m), 7.67 - 7.71 (2H, m); Mass (m/z): 377.3 (M+H) ⁺ .
25	7.	3-[2-Fluoro-4-(1-cyclobutyl piperidin-4-yloxy) phenyl]-1-(morpholin-4-yl) prop-2-ene-1-one L(+)-Tartarate salt	¹ H - NMR (δ ppm): 1.60 - 1.70 (4H, m), 1.80 - 1.90 (2H, m), 1.99 - 2.09 (3H, m), 2.14 - 2.20 (2H, m), 2.40 - 2.51 (4H, m), 2.70 - 2.76 (2H, m), 3.00 - 3.09 (1H, m), 3.48 (2H, s), 3.60 - 3.80 (6H, m), 4.53 (2H, m), 6.61 - 6.70 (2H, m), 6.85 - 6.89 (1H, d, J = 15.56 Hz), 7.39 - 7.43 (1H, m), 7.65 - 7.69 (1H, d,
30			J = 15.56 Hz); Mass (m/z): 389.4 (M+H) ⁺ .
35	8.	3-[4-(1-Cyclobutyl piperidin-4-yloxy)-2-methyl phenyl]-1-(morpholin-4-yl) prop-2-ene-1-one L(+)-Tartarate salt	¹ H - NMR (δ ppm): 1.81 - 1.91 (3H, m), 2.11 - 2.33 (9H, m), 2.41 (3H, s), 3.14 - 3.20 (4H, m), 3.71 (8H, s), 4.43 (2H, s), 6.85 - 6.93 (3H, m), 7.67 - 7.69 (1H, d, J = 8.3 Hz), 7.85 - 7.89 (1H, d, J = 15. Hz); Mass (m/z): 385.4 (M+H) ⁺ .
40	9.	3-[4-(1-Isopropyl piperidin-4-yloxy)-2-methyl phenyl]-1-(morpholin-4-yl) prop-2-ene-1-one L(+)-Tartarate salt	¹ H - NMR (δ ppm): 1.38 - 1.40 (6H, d), 1.91 - 1.98 (1H, m), 2.16 - 2.30 (4H, m), 2.42 (3H, s), 3.34 - 3.57 (3H, m), 3.71 (8H, s), 4.41 (2H, s), 4.75 (2H, m), 6.86 - 6.95 (3H, m), 7.69 - 7.71 (1H, d, J = 8.45 Hz), 7.86 - 7.90 (1H, d, J = 15.28 Hz) Mass (m/z): 373.4 (M+H) ⁺ .
45	10.	3-[4-(1-Cyclobutyl piperidin-4-yloxy) phenyl]-1-(morpholin-4-yl) prop-2-ene-1-one L(+)-Tartarate salt	¹ H - NMR (δ ppm): 1.60 - 1.65 (2H, m), 1.73 - 1.77 (2H, m), 2.01 - 2.09 (6H, m), 2.49 - 2.52 (2H, m), 2.81 - 2.89 (2H, m), 3.14 - 3.19 (1H, m), 3.50 - 3.70 (8H, m), 4.46 (2H, s), 4.50-4.60 (1H, m), 6.97 - 6.99 (2H, d, J = 8.45 Hz), 7.07 - 7.10 (1H, d, J = 15.32 Hz), 7.43 - 7.47 (1H, d, J = 15.27 Hz), 7.63 - 7.65 (2H, d, J = 8.45 Hz); Mass (m/z): 371.3 (M+H) ⁺ .
50	11.	3-[4-(1-Cyclobutyl piperidin-4-yloxy)-3-methoxy phenyl]-1-(morpholin-4-yl) prop-2-ene-1-one L(+)-Tartarate salt	¹ H - NMR (δ ppm): 1.86 - 1.93 (3H, m), 2.14 - 2.38 (9H, m), 3.15 - 3.25 (3H, m), 3.72 (8H, s), 3.92 (3H, s), 4.46 (2H, s), 4.71 - 4.77 (1H, m), 7.06 - 7.10 (2H, m), 7.19 - 7.21 (1H, d, J = 7.7 Hz), 7.35 (1H, s), 7.54 - 7.58 (1H, d, J = 15.37 Hz); Mass (m/z): 401.3 (M+H) ⁺ .

55

(continued)

5	12.	3-[4-(1-Cyclopropylmethyl piperidin-4-yloxy)-3-methoxy phenyl]-1-(morpholin-4-yl) prop-2-ene-1-one L(+)-Tartarate salt	¹ H - NMR (δ ppm): 0.46 - 0.48 (2H, m), 0.78 - 0.83 (2H, m), 1.15 - 1.19 (1H, m), 1.33 - 1.39 (2H, m), 2.17 - 2.26 (4H, m) 3.07 - 3.10 (2H, m), 3.41 - 3.52 (2H, m) 3.72 (8H, s), 3.92 (3H, s), 4.46 (2H, s), 4.69 (1H, m), 7.05 - 7.09 (2H, m), 7.20 - 7.22 (1H, d, J = 8.2 Hz), 7.35 (1H, s), 7.54 - 7.58 (1H, d, J = 15.37 Hz); Mass (m/z): 401.4 (M+H) ⁺ .
10	13.	3-[4-(1-Isobutyl piperidin-4-yloxy)-3-methoxy phenyl]-1-(morpholin-4-yl) prop-2-ene-1-one L(+)-Tartarate salt	¹ H - NMR (δ ppm): 1.03 - 1.05 (6H, d), 2.13 - 2.15 (5H, m), 2.96 - 2.98 (2H, m), 3.39 - 3.45 (4H, m), 3.68 - 3.81 (8H, m), 3.88 (3H, s), 4.39 (2H, s), 4.65 (1H, m), 7.05 - 7.09 (2H, m), 7.15-7.17 (1H, d, J = 8.28 Hz), 7.31 (1H, s), 7.50 - 7.54 (1H, d, J = 15.36 Hz); Mass (m/z): 403.4 (M+H) ⁺ .
15	14.	3-[4-(1-Isopropyl piperidin-4-yloxy)-3-methoxy phenyl]-1-(morpholin-4-yl) prop-2-ene-1-one L(+)-Tartarate salt	¹ H - NMR (δ ppm): 1.40 - 1.42 (6H, d), 1.92 - 1.96 (1H, m), 2.14 - 2.31 (4H, m), 3.48 - 3.49 (4H, m), 3.72 - 3.93 (8H, s), 3.93 (3H, s), 4.44 (2H, s), 4.80 - 4.82 (1H, m), 7.06 - 7.10 (2H, m), 7.20 - 7.22 (1H, d, J = 7.76 Hz), 7.35 (1H, s) 7.54 - 7.58 (1H, d, J = 15.37 Hz); Mass (m/z): 389.4 (M+H) ⁺ .
20	15.	3-[4-(1-Isopropyl piperidin-4-yloxy)-3-methoxy phenyl]-1-(piperidin-1-yl) prop-2-ene-1-one L(+)-Tartarate salt	¹ H - NMR (δ ppm): 1.36 - 1.38 (6H, d), 1.60 - 1.62 (4H, m), 1.69 - 1.70 (2H, m), 2.14 (4H, bs), 3.44 - 3.46 (4H, m), 3.53-3.56 (1H, m), 3.63 - 3.75 (4H, m), 3.89 (3H, s), 4.39 (2H, s), 4.64 - 4.66 (1H, m), 7.03 - 7.07 (2H, m), 7.14 - 7.16 (1H, d, J = 8.21 Hz), 7.29 (1H, s), 7.45 - 7.49 (1H, d, J = 15.53 Hz); Mass (m/z): 387.4 (M+H) ⁺ .
25	16.	3-[4-(1-Cyclobutyl piperidin-4-yloxy)-3-methoxy phenyl]-1-(piperidin-1-yl) prop-2-ene-1-one L(+)-Tartarate salt	¹ H - NMR (δ ppm): 0.46 - 0.48 (2H, m), 0.81 - 0.83 (2H, m), 1.18 - 1.21 (2H, m), 1.34 - 1.30 (2H, d, J = 6.56 Hz), 1.62 - 1.64 (4H, m), 1.73 - 1.75 (2H, m), 2.18 (4H, bs), 3.08 - 3.10 (2H, m), 3.39 - 3.50 (1H, m), 3.67 - 3.73 (4H, m), 3.93 (3H, s), 4.45 (2H, s), 4.70 - 4.76 (1H, m), 7.07 - 7.11 (2H, m), 7.18-7.20 (1H, d, J = 8.23 Hz), 7.34 (1H, s), 7.49 - 7.53 (1H, d, J = 15.38 Hz); Mass (m/z): 399.5 (M+H) ⁺ .
30	17.	3-[4-(1-Cyclopropylmethyl piperidin-4-yloxy) phenyl]-1-(morpholin-4-yl) prop-2-ene-1-one	¹ H - NMR (δ ppm): 0.09 - 0.12 (2H, d), 0.50 - 0.54 (2H, d), 0.85 - 0.89 (1H, m), 1.81 - 1.90 (2H, m), 2.01 - 2.05 (2H, m), 2.27 - 2.28 (2H, d), 2.38 - 2.41 (2H, m), 2.83 - 2.89 (2H, m), 3.62 - 3.72 (8H, m), 4.35 - 4.37 (1H, m), 6.68 - 6.72 (1H, d, J = 15.30 Hz), 6.88 - 6.90 (2H, m, J = 8.64 Hz), 7.44 - 7.46 (2H, m, J = 8.63 Hz), 7.63 - 7.67 (1H, d, J = 15.33 Hz); Mass (m/z): 371.2 (M+H) ⁺ .
35	18.	3-[4-(1-Isobutyl piperidin-4-yloxy) phenyl]-1-(morpholin-4-yl) prop-2-ene-1-one	¹ H - NMR (δ ppm): 0.89 - 0.90 (6H, d), 1.73 - 1.84 (3H, m), 1.97 - 2.00 (2H, m), 2.08 - 2.10 (2H, d), 2.18 - 2.23 (2H, m), 2.68 - 2.70 (2H, m), 3.62 - 3.72 (8H, m), 4.31 - 4.35 (1H, m), 6.68 - 6.71 (1H, d, J = 15.38 Hz), 6.87 - 6.89 (2H, m, J = 8.62 Hz), 7.44 - 7.46 (2H, m, J = 8.65 Hz), 7.63 - 7.67 (1H, d, J = 15.30 Hz); Mass (m/z): 373.4 (M+H) ⁺ .
40	19.	3-[3-Bromo-4-(1-isopropyl piperidin-4-yloxy) phenyl]-1-(morpholin-4-yl) prop-2-ene-1-one	¹ H - NMR (δ ppm): 1.25 - 1.27 (6H, d), 2.01 - 2.06 (1H, m), 2.11-2.14 (2H, m), 2.61 - 2.68 (2H, m), 3.11 - 3.18 (2H, m), 3.23 - 3.27 (2H, m), 3.66 - 3.73 (8H, m), 4.79 - 4.80 (1H, m), 6.71 - 6.75 (1H, d, J = 15.32 Hz), 6.90 - 6.92 (1H, d, J = 8.50 Hz), 7.42 - 7.44 (1H, dd, J = 8.49 Hz), 7.56 - 7.60 (1H, d, J = 15.33 Hz) 7.74 (1H, d, J = 1.56 Hz); Mass (m/z): 437.3, 439.2 (M+H) ⁺ .
45			
50			

55

(continued)

5	20.	3-[3-Bromo-4-(1-cyclobutyl piperidin-4-yloxy) phenyl]-1-(morpholin-4-yl) prop-2-ene-1-one	¹ H - NMR (δ ppm): 1.37 - 1.42 (2H, m), 1.57 - 1.61 (2H, m), 1.68 - 1.75 (2H, m), 1.84 (1H, m), 2.01 - 2.04 (2H, m), 2.13 - 2.15 (2H, m), 2.31 - 2.32 (2H, m), 2.75 - 2.80 (2H, m), 3.66-3.72 (8H, m), 4.66 - 4.70 (1H, m), 6.69 - 6.73 (1H, d, J = 15.37 Hz), 6.88 - 6.90 (1H, d, J = 8.57 Hz), 7.38 - 7.41 (1H, dd, J = 8.34, 1.44 Hz), 7.56 - 7.60 (1H, d, J = 15.33 Hz) 7.74 (1H, d, J = 1.77 Hz); Mass (m/z): 449.3, 451.2 (M+H) ⁺ .
10	21.	3-[3-Bromo-4-(1-isobutyl piperidin-4-yloxy) phenyl]-1-(morpholin-4-yl) prop-2-ene-1-one	¹ H - NMR (δ ppm): 1.25 - 1.27 (6H, d), 1.62 - 1.71 (4H, m), 1.94 - 1.99 (2H, m), 2.01 - 2.06 (1H, m), 2.21 - 2.39 (2H, m), 2.76 - 2.80 (2H, m), 3.67 - 3.72 (8H, m), 4.50 - 4.53 (1H, m), 6.69 - 6.72 (1H, d, J = 15.36 Hz), 6.87 - 6.90 (1H, d, J = 8.55 Hz), 7.36 - 7.38 (1H, d, J = 8.39 Hz), 7.56 - 7.60 (1H, d, J = 15.35 Hz), 7.75 (1H, d, J = 1.86 Hz); Mass (m/z): 451.2, 453.3 (M+H) ⁺ .
15	22.	3-[3-Bromo-4-(1-cyclopropylmethyl piperidin-4-yloxy) phenyl]-1-(morpholin-4-yl) prop-2-ene-1-one	¹ H - NMR (δ ppm): 0.29 - 0.31 (2H, d), 0.66 - 0.68 (2H, d), 1.11 - 1.15 (1H, m), 2.05 - 2.08 (2H, m), 2.38 - 2.42 (2H, m), 2.62 - 2.70 (2H, m), 3.03 - 3.10 (4H, m), 3.66 - 3.72 (8H, m), 4.68 - 4.71 (1H, m), 6.70 - 6.73 (1H, d, J = 15.33 Hz), 6.89 - 6.91 (1H, d, J = 8.55 Hz), 7.39 - 7.41 (1H, d, J = 8.46 Hz),
20			7.56 - 7.60 (1H, d, J = 15.31 Hz) 7.74 - 7.75 (1H, d, J = 1.60 Hz); Mass (m/z): 449.3, 451.2 (M+H) ⁺ .
25	23.	3-[6-(1-Cyclopropylmethyl piperidin-4-yloxy) pyridin-3-yl]-1-(morpholin-4-yl) prop-2-ene-1-one L(+)-Tartarate salt	¹ H - NMR (δ ppm): 0.44 - 0.47 (2H, m), 0.76 - 0.81 (2H, m), 1.16 - 1.19 (1H, m), 1.28 - 1.30 (1H, m), 2.19 - 2.30 (4H, m), 3.06 - 3.08 (2H, d), 3.35 - 3.49 (3H, bs), 3.72 - 3.76 (8H, m), 4.42 (2H, s), 5.39 (1H, bs), 6.88 - 6.90 (1H, d, J = 8.64 Hz), 7.10 - 7.14 (1H, d, J = 15.46 Hz), 7.56 - 7.60 (1H, d, J = 15.46 Hz), 8.09 - 8.11 (1H, dd, J = 8.61, 2.21 Hz), 8.34 - 8.35 (1H, d, J = 2 Hz); Mass (m/z): 372.4 (M+H) ⁺ .
30	24.	3-[6-(1-Isobutyl piperidin-4-yloxy) pyridin-3-yl]-1-(morpholin-4-yl) prop-2-ene-1-one L(+)-Tartarate salt	¹ H - NMR (δ ppm): 1.08 - 1.09 (6H, d), 1.28 - 1.30 (1H, m), 1.39 - 1.42 (1H, m), 2.18 - 2.31 (4H, m), 3.03 - 3.05 (2H, d), 3.35 - 3.49 (3H, m), 3.72 - 3.76 (8H, m), 4.47 (2H, s), 5.40 (1H, bs), 6.88 - 6.90 (1H, d, J = 8.59 Hz), 7.11 - 7.15 (1H, d, J = 15.46 Hz), 7.56 - 7.60 (1H, d, J = 15.46 Hz), 8.09 - 8.12 (1H, dd, J = 8.52, 1.86 Hz), 8.34 - 8.35 (1H, d, J = 1.86 Hz); Mass (m/z): 374.4 (M+H) ⁺ .
35	25.	3-[2-Chloro-4-(1-cyclobutyl piperidin-4-yloxy) phenyl]-1-(morpholin-4-yl) prop-2-ene-1-one	¹ H - NMR (δ ppm): 1.69 - 1.76 (4H, d), 1.82 - 1.94 (3H, m), 2.00 - 2.09 (3H, m), 2.21 - 2.25 (2H, m), 2.59 - 2.63 (2H, m), 2.73 - 2.79 (1H, m), 3.70 - 3.76 (8H, m), 4.11- 4.16 (1H, bs), 6.74 - 6.78 (1H, d, J = 15.41 Hz), 6.82 - 6.85 (1H, dd, J = 8.71, 2.2 Hz), 6.97 - 6.98 (1H, d, J = 2.23 Hz), 7.53 - 7.55 (1H, dd, J = 8.71 Hz), 7.99 - 8.03 (1H, d, J = 15.42 Hz); Mass (m/z): 405.3, 407.4 (M+H) ⁺ .
40	26.	3-[2-Chloro-4-(1-isopropyl piperidin-4-yloxy) phenyl]-1-(morpholin-4-yl) prop-2-ene-1-one	¹ H - NMR (δ ppm): 1.05 - 1.06 (6H, d), 1.78 - 1.85 (2H, m), 1.99 - 2.09 (2H, m), 2.38 - 2.43 (2H, t), 2.72 - 2.78 (3H, m), 3.66 - 3.72 (8H, s), 4.30 - 4.33 (1H, m), 6.71 - 6.74 (1H, d, J = 15.33 Hz), 6.79 - 6.81 (1H, dd, J = 8.71, 2.07 Hz), 6.94 - 6.95 (1H, d, J = 2.4 Hz), 7.49 - 7.52 (1H, d, J = 8.73 Hz), 7.96 - 7.99 (1H, d, J = 15.39 Hz); Mass (m/z): 393.2, 395.2 (M+H) ⁺ .
45			
50			

55

(continued)

27.	3-[2-Chloro-4-(1-cyclopropylmethyl piperidin-4-yloxy) phenyl]-1-(morpholin-4-yl) prop-2-ene-1-one	¹ H - NMR (δ ppm): 0.13 - 0.19 (2H, m), 0.54 - 0.59 (2H, m), 0.90 - 0.91 (1H, m), 1.87 - 1.93 (2H, m), 2.04 - 2.09 (2H, m), 2.31 - 2.32 (2H, d), 2.43 (2H, m), 2.86 (2H, m), 3.69 - 3.76 (8H, m), 4.37 - 4.38 (1H, m), 6.74 - 6.78 (1H, d, J = 15.41 Hz), 6.83 - 6.86 (1H, dd, J = 8.72, 2.22 Hz), 6.98 - 6.99 (1H, d, J = 2.41 Hz), 7.54 - 7.56 (1H, d, J = 8.71 Hz), 8.00 - 8.03 (1H, d, J = 15.46 Hz); Mass (m/z): 405.3, 407.4 (M+H) ⁺ .
28.	3-[2-Chloro-4-(1-isobutyl piperidin-4-yloxy) phenyl]-1-(morpholin-4-yl) prop-2-ene-1-one	¹ H - NMR (δ ppm): 0.93 - 0.94 (6H, d), 1.77 - 1.87 (3H, m), 2.00 - 2.04 (2H, m), 2.12 - 2.14 (2H, d), 2.23 - 2.28 (2H, t), 2.72 (2H, m), 3.70 - 3.76 (8H, s), 4.32 - 4.36 (1H, m), 6.74 - 6.78 (1H, d, J = 15.45 Hz), 6.82 - 6.85 (1H, dd, J = 8.72, 2.35 Hz), 6.97 - 6.98 (1H, d, J = 2.24 Hz), 7.53 - 7.55 (1H, d, J = 8.76 Hz), 8.00 - 8.03 (1H, d, J = 15.41 Hz); Mass (m/z): 407.3, 409.2 (M+H) ⁺ .

Biological Assays**Example 29: Binding and functional assays for human or rat histamine H3 receptor**

[0040] Compounds can be evaluated according to the following procedures.

Materials and Methods:

[0041] Receptor source: Rat brain frontal cortex or recombinant human cDNA expressed in CHO cells

Radioligand: [³H] R-α-methylhistamine

Final ligand concentration - [3.0 nM]

Non-specific determinant: R-α-methylhistamine (100 μM)

Reference compound: R-α-methylhistamine

Positive control: R-α-methylhistamine

Incubation conditions:

[0042] Increasing concentrations of test compounds or standard were incubated with membrane receptors and radioligand in 5 mM MgCl₂ and 50 mM TRIS-HCl (pH 7.4) for 60 minutes at room temperature. The reaction was terminated by rapid vacuum filtration onto the glass fiber filters. Radioactivity trapped onto the filters was determined and compared to the control values in order to ascertain any interactions of the test compound(s) with either cloned human or rat receptor binding site.

Example Number	K _i (nM)
1.	1.32
2.	1.82
3.	1.40
4.	7.82
5.	7.90
6.	17.49
7.	2.96
8.	6.34
9.	13.10
10.	3.43
11.	77.18

(continued)

Example Number	K _i (nM)
18.	32.35
19.	16.97
20.	5.97
22.	52.62
25.	29.71

Example 30: Rodent Pharmacokinetic Study

[0043] Male Wistar rats (230 - 280 grams) were used as experimental animals. Three to five animals were housed in each cage. One day prior to dosing day, male wistar rats (225 - 250 grams) were anesthetized with isoflurane for surgical placement of jugular vein catheter. Animals were kept fasted over night and maintained on a 12 hours light/dark cycle. Three rats were dosed with compounds of formula (I) orally (3 mg/Kg) and intravenously (1 mg/kg) in two separate set of animals (n = 3 rats/ group).

[0044] At each time point, blood was collected by jugular vein. Blood was stored frozen at 4 °C until analysis. The concentrations of the compounds of formula (I) in blood were determined using LC-MS/MS method. Schedule time point: Pre dose 0.08 (only for i.v.) 0.25, 0.5, 1, 2, 4, 6, 8, and 24 hours after dosing (n=3). The compounds of formula (I) were quantified in blood by validated LC-MS/MS method using acetonitrile precipitation technique. The compounds of formula (I) were quantified in the calibration range of 1-1000 ng/mL in blood. Study samples were analyzed using calibration samples in the batch and quality control samples spread across the batch.

[0045] Pharmacokinetic parameters C_{max}, T_{max}, AUC_t, T_{1/2} and Bioavailability were calculated by non-compartmental model using software Pheonix WinNonlin version 6.0.1.

Example Number	Strain/ Sex	Dose (mg/kg)	Vehicle	Route of administration	C _{max} (ng/mL)	T _{max} (h)	AUC _t (ng.hr/mL)	T _{1/2} (h)	Bioavailability (%)
1.	Wistar rats/ Male	3	Reagent grade water	Per-Oral	106 ± 5	0.50 ± 0.00	176 ± 10	1.56 0.43	29 ± 2
		1	Sterile water for injection	Intravenous	214 ± 25	0.08 ± 0.00	208 ± 7	0.00 ± 0.07	
5.	Wistar rats/ Male	3	Reagent grade water	Per-Oral	128 ± 6	0.42 ± 0.14	184 ± 25	1.1 0.3	35 ± 5
		1	Sterile water for injection	Intravenous	220 ± 10	0.08 ± 0.00	173 ± 13	0.6 ± 0.20	
7.	Wistar rats/ Male	3	Reagent grade water	Per-Oral	57 ± 36	0.25 ± 0.00	49 ± 29	0.9 0.6	9 ± 5
		1	Sterile water for injection	Intravenous	311 ± 110	0.08 ± 0.00	167 ± 47	0.6 ± 0.2	
10.	Wistar rats/ Male	3	Reagent grade water	Per-Oral	290 ± 32	0.25 ± 0.00	387 ± 38	0.85 0.14	58 ± 6
		1	Sterile water for injection	Intravenous	285 ± 46	0.08 ± 0.00	222 ± 33	0.80 0.05	

Example 31: Rodent Brain Penetration Study

[0046] Male Wistar rats (230 - 280 grams) were used as experimental animals. Three animals were housed in each cage. Animals were given water and food ad libitum throughout the experiment and maintained on a 12 hours light/dark cycle.

[0047] Brain penetration was determined in discrete manner in rats. One day prior to dosing day, male wistar rats (225 - 250 grams) were acclimatized. After acclimatization, the rats were grouped according to the weight in each group, 3 animals were kept in individual cage and allowed free access to food and water. At each time point (05, 1, and 2 hrs) n=3 animals were used.

[0048] The compounds of formula (I) were dissolved in water and administered orally at (free base) 3 mg/kg. Blood samples were removed via, cardiac puncture by using light ether anesthesia the animals were sacrificed to collect brain tissue. Brain samples were homogenized and stored frozen at -20 °C until analysis. The concentrations of the compounds of formula (I) in blood and brain were determined using LC-MS/MS method.

[0049] The compounds of formula (I) were quantified in blood and brain homogenate by validated LC-MS/MS method using acetonitrile precipitation technique. The compounds of formula (I) were quantified in the calibration range of 1-1000 ng/mL in blood and brain homogenate. Study samples were analyzed using calibration samples in the batch and quality control samples spread across the batch. Extents of brain to blood ratios were calculated ($C_{\text{brain}}/C_{\text{blood}}$).

Example Number	Strain/ Sex	Dose (mg/kg)	Vehicle	Route of administration	Brain Penetration @ 1 h post dose ($C_{\text{brain}}/C_{\text{blood}}$)
1.	Wister rats/ Male	3	Reagent grade water	Per-oral	1.40
5.	Wister rats/ Male	3	Reagent grade water	Per-oral	0.92
7.	Wister rats/ Male	3	Reagent grade water	Per-oral	2.51
10.	Wister rats/ Male	3	Reagent grade water	Per-oral	1.36

Example 32: Object Recognition Task Model

[0050] The cognition enhancing properties of compounds of this invention were estimated using a model of animal cognition: the object recognition task model.

[0051] Male Wister rats (230 - 280 grams) were used as experimental animals. Four animals were housed in each cage. Animals were kept on 20 % food deprivation before one day and given water ad libitum throughout the experiment and maintained on a 12 hours light/dark cycle. Also the rats were habituated to individual arenas for 1 hour in the absence of any objects.

[0052] One group of 12 rats received vehicle (1 mL/Kg) orally and another set of animals received compound of the formula (I) either orally or i.p., before one hour of the familiar (T1) and choice trial (T2).

[0053] The experiment was carried out in a 50 x 50 x 50 cm open field made up of acrylic. In the familiarization phase, (T1), the rats were placed individually in the open field for 3 minutes, in which two identical objects (plastic bottles, 12.5 cm height x 5.5 cm diameter) covered in yellow masking tape alone (a1 and a2) were positioned in two adjacent corners, 10 cm. from the walls. After 24 hours of the (T1) trial for long-term memory test, the same rats were placed in the same arena as they were placed in T1 trial. Choice phase (T2) rats were allowed to explore the open field for 3 minutes in presence of one familiar object (a3) and one novel object (b) (Amber color glass bottle, 12 cm high and 5 cm in diameter). Familiar objects presented similar textures, colors and sizes. During the T1 and T2 trial, explorations of each object (defined as sniffing, licking, chewing or having moving vibrissae whilst directing the nose towards the object at a distance of less than 1 cm) were recorded separately by stopwatch. Sitting on an object was not regarded as exploratory activity, however, it was rarely observed.

[0054] T1 is the total time spent exploring the familiar objects (a1 + a2).

[0055] T2 is the total time spent exploring the familiar object and novel object (a3 + b).

[0056] The object recognition test was performed as described by Ennaceur, A., Delacour, J., 1988, A new one-trial test for neurobiological studies of memory in rats - Behavioural data, Behav. Brain Res., 31, 47-59.

[0057] Some representative compounds have shown positive effects indicating the increased novel object recognition viz; increased exploration time with novel object and higher discrimination index.

Example Number	Dose mg/kg, p.o.	Exploration time mean $\pm$ S.E.M (sec)		Inference
		Familiar object	Novel object	
1.	1 mg/kg	5.96 $\pm$ 1.03	14.86 $\pm$ 1.92	Active
5.	3 mg/kg	9.64 $\pm$ 2.22	15.53 $\pm$ 2.36	Active


Example 33: Water Maze

[0058] The water maze apparatus consisted of a circular pool (1.8 m diameter, 0.6 m high) constructed in black Perspex (TSE systems, Germany) filled with water ($24 \pm 2^\circ\text{C}$) and positioned underneath a wide-angled video camera to track animal. The 10 cm² perspex platform, lying 1 cm below the water surface, was placed in the centre of one of the four imaginary quadrants, which remained constant for all rats. The black Perspex used in the construction of the maze and platform offered no intramaze cues to guide escape behavior. By contrast, the training room offered several strong extramaze visual cues to aid the formation of the spatial map necessary for escape learning. An automated tracking system, [Videomot 2 (5.51), TSE systems, Germany] was employed. This program analyzes video images acquired via a digital camera and an image acquisition boards that determined path length, swim speed and the number of entries and duration of swim time spent in each quadrant of the water maze.

Example Number	Reversal of Scopolamine Induced amnesia
10.	3 & 10 mg/kg, s.c.


Claims

1. A compound of the general formula (I):



wherein,

- R₁ is independently selected from hydrogen, halogen, alkyl or alkoxy;
- "A" is alkyl, cycloalkyl or cycloalkylalkyl;
- "X" is CH or N;
- "Y" is CH₂, O or



or its pharmaceutically acceptable salts.

2. The compound according to claim 1, which is selected from the group consisting of:


- 3-[4-(1-Cyclobutyl piperidin-4-yloxy) phenyl]-1-(morpholin-4-yl) prop-2-ene-1-one fumarate salt;
- 3-[4-(1-Cyclobutyl piperidin-4-yloxy) phenyl]-1-(piperidin-1-yl) prop-2-ene-1-one hydrochloride salt;
- 3-[4-(1-Cyclobutyl piperidin-4-yloxy) phenyl]-1-(1,1-dioxo thiomorpholin-4-yl) prop-2-ene-1-one hydrochloride salt;

3-[2-(1-Cyclobutyl piperidin-4-yloxy) pyridin-5-yl]-1-(piperidin-1-yl) prop-2-ene-1-one L(+)-Tartarate salt;
 3-[2-(1-Cyclobutyl piperidin-4-yloxy) pyridin-5-yl]-1-(morpholin-4-yl) prop-2-ene-1-one L(+)-Tartarate salt;
 3-[2-Fluoro-4-(1-isopropyl piperidin-4-yloxy) phenyl]-1-(morpholin-4-yl) prop-2-ene-1-one L(+)-Tartarate salt;
 3-[2-Fluoro-4-(1-cyclobutyl piperidin-4-yloxy) phenyl]-1-(morpholin-4-yl) prop-2-ene-1-one L(+)-Tartarate salt;
 3-[4-(1-Cyclobutyl piperidin-4-yloxy)-2-methyl phenyl]-1-(morpholin-4-yl) prop-2-ene-1-one L(+)-Tartarate salt;
 3-[4-(1-Isopropyl piperidin-4-yloxy)-2-methyl phenyl]-1-(morpholin-4-yl) prop-2-ene-1-one L(+)-Tartarate salt;
 3-[4-(1-Cyclobutyl piperidin-4-yloxy) phenyl]-1-(morpholin-4-yl) prop-2-ene-1-one L(+)-Tartarate salt;
 3-[4-(1-Cyclobutyl piperidin-4-yloxy)-3-methoxy phenyl]-1-(morpholin-4-yl) prop-2-ene-1-one L(+)-Tartarate
 salt;
 3-[4-(1-Cyclopropylmethyl piperidin-4-yloxy)-3-methoxy phenyl]-1-(morpholin-4-yl) prop-2-ene-1-one L(+)-Tar-
 tarate salt;
 3-[4-(1-Isobutyl piperidin-4-yloxy)-3-methoxy phenyl]-1-(morpholin-4-yl) prop-2-ene-1-one L(+)-Tartarate salt;
 3-[4-(1-Isopropyl piperidin-4-yloxy)-3-methoxy phenyl]-1-(morpholin-4-yl) prop-2-ene-1-one L(+)-Tartarate salt;
 3-[4-(1-Isopropyl piperidin-4-yloxy)-3-methoxy phenyl]-1-(piperidin-1-yl) prop-2-ene-1-one L(+)-Tartarate salt;
 3-[4-(1-Cyclobutyl piperidin-4-yloxy)-3-methoxy phenyl]-1-(piperidin-1-yl) prop-2-ene-1-one L(+)-Tartarate salt;
 3-[4-(1-Cyclopropylmethyl piperidin-4-yloxy) phenyl]-1-(morpholin-4-yl) prop-2-ene-1-one;
 3-[4-(1-Isobutyl piperidin-4-yloxy) phenyl]-1-(morpholin-4-yl) prop-2-ene-1-one;
 3-[3-Bromo-4-(1-isopropyl piperidin-4-yloxy) phenyl]-1-(morpholin-4-yl) prop-2-ene-1-one;
 3-[3-Bromo-4-(1-cyclobutyl piperidin-4-yloxy) phenyl]-1-(morpholin-4-yl) prop-2-ene-1-one;
 3-[3-Bromo-4-(1-cyclobutyl piperidin-4-yloxy) phenyl]-1-(morpholin-4-yl) prop-2-ene-1-one;
 3-[3-Bromo-4-(1-cyclopropylmethyl piperidin-4-yloxy) phenyl]-1-(morpholin-4-yl) prop-2-ene-1-one;
 3-[6-(1-Cyclopropylmethyl piperidin-4-yloxy) pyridin-3-yl]-1-(morpholin-4-yl) prop-2-ene-1-one L(+)-Tartarate
 salt;
 3-[6-(1-Isobutyl piperidin-4-yloxy) pyridin-3-yl]-1-(morpholin-4-yl) prop-2-ene-1-one L(+)-Tartarate salt;
 3-[2-Chloro-4-(1-cyclobutyl piperidin-4-yloxy) phenyl]-1-(morpholin-4-yl) prop-2-ene-1-one;
 3-[2-Chloro-4-(1-isopropyl piperidin-4-yloxy) phenyl]-1-(morpholin-4-yl) prop-2-ene-1-one;
 3-[2-Chloro-4-(1-cyclopropylmethyl piperidin-4-yloxy) phenyl]-1-(morpholin-4-yl) prop-2-ene-1-one; and
 3-[2-Chloro-4-(1-isobutyl piperidin-4-yloxy) phenyl]-1-(morpholin-4-yl) prop-2-ene-1-one;

or their pharmaceutically acceptable salts.

3. The process for preparation of a compound of formula (I) as claimed in claim 1, which comprises:

(a) reductive amination of the compound of formula (1) with compound of formula (2)



in presence of a suitable solvent and reducing agent to form a compound of formula (I), wherein all substitutions are as defined in claim 1,

(b) optionally converting the compound of formula (I) to their pharmaceutically acceptable salts.

4. A pharmaceutical composition comprising a compound according to claim 1 and pharmaceutically acceptable excipients.

5. the pharmaceutical composition according to claim 4, for use in the treatment of clinical conditions mediated through H₃ receptor selected from cognitive deficits in schizophrenia, narcolepsy, obesity, attention deficit hyperactivity disorder, pain or alzheimer's disease.

6. The compound as claimed in any one of the claim 1 or claim 2 for use in the treatment of cognitive deficits in


schizophrenia, narcolepsy, obesity, attention deficit hyperactivity disorder, pain or alzheimer's disease.

7. Use of a compound according to claim 1 in the manufacture of medicament for the treatment of diseases related to Histamine H₃ receptors.

8. The use of compound in the manufacture of a medicament according to the claim 7, for the treatment of clinical conditions selected from cognitive deficits in schizophrenia, narcolepsy, obesity, attention deficit hyperactivity disorder, pain or alzheimer's disease.


Patentansprüche

1. Eine Verbindung der allgemeinen Formel (I):



wobei,

R₁ unabhängig ausgewählt wird aus Wasserstoff, Halogen, Alkyl oder Alkoxy;
 "A" Alkyl, Cycloalkyl oder Cycloalkylalkyl ist;
 "X" CH oder N ist;
 "Y" CH₂, O oder



ist

oder seine pharmazeutisch verträglichen Salze.

2. Verbindung gemäß Anspruch 1, die ausgewählt wird aus der Gruppe bestehend aus:

3-[4-(1-Cyclobutyl-piperidin-4-yloxy)-phenyl]-1-(morpholin-4-yl)-prop-2-ene-1-eins Fumaratsalz;
 3-[4-(1-Cyclobutyl-piperidin-4-yloxy)-phenyl]-1-(piperidin-1-yl)-prop-2-ene-1-eins Hydrochloridsalz;
 3-[4-(1-Cyclobutyl-piperidin-4-yloxy)-phenyl]-1-(1,1-dioxo-thiomorpholin-4-yl)-prop-2-ene-1-eins Hydrochlorid-
 salz;
 3-[2-(1-Cyclobutyl-piperidin-4-yloxy)-pyridin-5-yl]-1-(piperidin-1-yl)-prop-2-ene-1-eins L(+)-Tartratsalz;
 3-[2-(1-Cyclobutyl-piperidin-4-yloxy)-pyridin-5-yl]-1-(morpholin-4-yl)-prop-2-ene-1-eins L(+)-Tartratsalz;
 3-[2-Fluor-4-(1-isopropyl-piperidin-4-yloxy)-phenyl]-1-(morpholin-4-yl)-prop-2-ene-1-eins L(+)-Tartratsalz;
 3-[2-Fluor-4-(1-cyclobutyl-piperidin-4-yloxy)-phenyl]-1-(morpholin-4-yl)-prop-2-ene-1-eins L(+)-Tartratsalz;
 3-[4-(1-Cyclobutyl-piperidin-4-yloxy)-2-methylphenyl]-1-(morpholin-4-yl)-prop-2-ene-1-eins L(+)-Tartratsalz;
 3-[4-(1-Isopropyl-piperidin-4-yloxy)-2-methylphenyl]-1-(morpholin-4-yl)-prop-2-ene-1-eins L(+)-Tartratsalz;
 3-[4-(1-Cyclobutyl-piperidin-4-yloxy)-phenyl]-1-(morpholin-4-yl)-prop-2-ene-1-eins L(+)-Tartratsalz;
 3-[4-(1-Cyclobutyl-piperidin-4-yloxy)-3-methoxyphenyl]-1-(morpholin-4-yl)-prop-2-ene-1-eins L(+)- Tartratsalz;
 3-[4-(1-Cyclopropylmethyl-piperidin-4-yloxy)-3-methoxyphenyl]-1-(morpholin-4-yl)-prop-2-en e-1-eins
 L(+)-Tartratsalz;
 3-[4-(1-Isobutyl-piperidin-4-yloxy)-3-methoxyphenyl]-1-(morpholin-4-yl)-prop-2-ene-1-eins L(+)- Tartratsalz;
 3-[4-(1-Isopropyl-piperidin-4-yloxy)-3-methoxyphenyl]-1-(morpholin-4-yl)-prop-2-ene-1-eins L(+)- Tartratsalz;


3-[4-(1-Isopropyl-piperidin-4-yloxy)-3-methoxyphenyl]-1-(piperidin-1-yl)-prop-2-ene-1-eins L(+)- Tartratsalz;
 3-[4-(1-Cyclobutyl-piperidin-4-yloxy)-3-methoxyphenyl]-1-(piperidin-1-yl)-prop-2-ene-1-one L(+)- Tartratsalz;
 3-[4-(1-Cyclopropylmethyl-piperidin-4-yloxy)-phenyl]-1-(morpholin-4-yl)-prop-2-ene-1-eins;
 3-[4-(1-Isobutyl-piperidin-4-yloxy) phenyl]-1-(morpholin-4-yl)-prop-2-ene-1-eins;
 3-[3-Brom-4-(1-isopropyl-piperidin-4-yloxy)-phenyl]-1-(morpholin-4-yl)-prop-2-ene-1-eins;
 3-[3-Brom-4-(1-cyclobutyl-piperidin-4-yloxy)-phenyl]-1-(morpholin-4-yl)-prop-2-ene-1-eins;
 3-[3-Brom-4-(1-isobutyl-piperidin-4-yloxy)-phenyl]-1-(morpholin-4-yl)-prop-2-ene-1-eins;
 3-[3-Brom-4-(1-cyclopropylmethyl-piperidin-4-yloxy)-phenyl]-1-(morpholin-4-yl)-prop-2-ene-1-eins;
 3-[6-(1-Cyclopropylmethyl-piperidin-4-yloxy)-pyridin-3-yl]-1-(morpholin-4-yl)-prop-2-ene-1-eins L(+)-Tartrat-
 3-[6-(1-Isobutyl-piperidin-4-yloxy)-pyridin-3-yl]-1-(morpholin-4-yl)-prop-2-ene-1-eins L(+)-Tartratsalz;
 3-[2-Chlor-4-(1-cyclobutyl-piperidin-4-yloxy)-phenyl]-1-(morpholin-4-yl)-prop-2-ene-1-eins;
 3-[2-Chlor-4-(1-isopropyl-piperidin-4-yloxy)-phenyl]-1-(morpholin-4-yl)-prop-2-ene-1-eins;
 3-[2-Chlor-4-(1-cyclopropylmethyl-piperidin-4-yloxy)-phenyl]-1-(morpholin-4-yl)-prop-2-ene-1-eins;

und

3-[2-Chlor-4-(1-isobutyl-piperidin-4-yloxy)-phenyl]-1-(morpholin-4-yl)-prop-2-ene-1-eins; oder deren pharmazeu-
 tisch verträgliche Salze.

3. Verfahren zur Zubereitung einer Verbindung der Formel (I) wie beansprucht in Anspruch 1, welches umfasst:

(a) reduktive Aminierung der Verbindung der Formel (1) mit einer Verbindung der Formel (2)



in Anwesenheit eines geeigneten Lösungsmittels und eines Reduktionsmittels, um eine Verbindung der Formel
 (I) zu bilden, in der alle Substitutionen so aussehen, wie in Anspruch 1 beschrieben,
 (b) optional Umwandlung der Verbindung der Formel (I) in ihre pharmazeutisch verträglichen Salze.

4. Pharmazeutische Zusammensetzung bestehend aus einer Verbindung gemäß Anspruch 1 und pharmazeutisch
 verträglichen Bestandteilen.

5. Pharmazeutische Zusammensetzung gemäß Anspruch 4 zur Verwendung in der Behandlung von klinischen Er-
 krankungen, die vermittelt werden durch den H₃-Rezeptor, ausgewählt aus kognitiven Defiziten bei Schizophrenie,
 Narkolepsie, Fettleibigkeit, Aufmerksamkeitsdefizit-Hyperaktivitätsstörung, Schmerzen oder Alzheimer.


6. Verbindung gemäß Anspruch 1 oder Anspruch 2 zur Verwendung in der Behandlung von kognitiven Defiziten bei
 Schizophrenie, Narkolepsie, Fettleibigkeit, Aufmerksamkeitsdefizit-Hyperaktivitätsstörung, Schmerzen oder Alzhei-
 mer.

7. Verwendung einer Verbindung gemäß Anspruch 1 in der Herstellung eines Medikaments zur Behandlung von
 Erkrankungen, die mit Histamin-H₃-Rezeptoren in Verbindung stehen.

8. Verwendung einer Verbindung in der Herstellung eines Medikaments gemäß Anspruch 7 zur Behandlung klinischer
 Erkrankungen, die ausgewählt werden aus kognitiven Defiziten bei Schizophrenie, Narkolepsie, Fettleibigkeit, Auf-
 merksamkeitsdefizit-Hyperaktivitätsstörung, Schmerzen oder Alzheimer.


Revendications

1. Composé de formule générale (I) :



dans laquelle,

R_1 est indépendamment choisi parmi un atome d'hydrogène, d'halogène, un groupe alkyle ou alcoxy ;
 « A » représente un groupe alkyle, cycloalkyle ou cycloalkylalkyle ;
 « X » représente un groupe CH ou un atome N ;
 « Y » représente un groupe CH_2 , un atome O ou



ou ses sels pharmaceutiquement acceptables.

2. Composé selon la revendication 1, qui est choisi dans le groupe constitué par :

le sel de fumarate de
 3-[4-(1-cyclobutylpipéridin-4-yloxy)phényl]-1-(morpholin-4-yl)prop-2-ène-1-one ;
 le sel de chlorhydrate de
 3-[4-(1-cyclobutylpipéridin-4-yloxy)phényl]-1-(pipéridin-1-yl)prop-2-ène-1-one ;
 le sel de chlorhydrate de
 3-[4-(1-cyclobutylpipéridin-4-yloxy)phényl]-1-(1,1-dioxothiomorpholin-4-yl)prop-2-ène-1-one ;
 le sel de L(+)-tartrate de
 3-[2-(1-cyclobutylpipéridin-4-yloxy)pyridin-5-yl]-1-(pipéridin-1-yl)prop-2-ène-1-one ;
 le sel de L(+)-tartrate de
 3-[2-(1-cyclobutylpipéridin-4-yloxy)pyridin-5-yl]-1-(morpholin-4-yl)prop-2-ène-1-one ;
 le sel de L(+)-tartrate de
 3-[2-fluoro-4-(1-isopropylpipéridin-4-yloxy)phényl]-1-(morpholin-4-yl)prop-2-ène-1-one ;
 le sel de L(+)-tartrate de
 3-[2-fluoro-4-(1-cyclobutylpipéridin-4-yloxy)phényl]-1-(morpholin-4-yl)prop-2-ène-1-one ;
 le sel de L(+)-tartrate de
 3-[4-(1-cyclobutylpipéridin-4-yloxy)-2-méthylphényl]-1-(morpholin-4-yl)prop-2-ène-1-one ;
 le sel de L(+)-tartrate de 3-[4-(1-isopropylpipéridin-4-yloxy)-2-méthylphényl]-1-(morpholin-4-yl) prop-2-ène-1-one ;
 le sel de L(+)-tartrate de
 3-[4-(1-cyclobutylpipéridin-4-yloxy)phényl]-1-(morpholin-4-yl)prop-2-ène-1-one ;
 le sel de L(+)-tartrate de
 3-[4-(1-cyclobutylpipéridin-4-yloxy)-3-méthoxyphényl]-1-(morpholin-4-yl)prop-2-ène-1-one ;
 le sel de L(+)-tartrate de
 3-[4-(1-cyclopropylméthylpipéridin-4-yloxy)-3-méthoxyphényl]-1-(morpholin-4-yl)prop-2-ène-1-one ;
 le sel de L(+)-tartrate de
 3-[4-(1-isobutylpipéridin-4-yloxy)-3-méthoxyphényl]-1-(morpholin-4-yl)prop-2-ène-1-one ;
 le sel de L(+)-tartrate de
 3-[4-(1-isopropylpipéridin-4-yloxy)-3-méthoxyphényl]-1-(morpholin-4-yl)prop-2-ène-1-one ;
 le sel de L(+)-tartrate de

3-[4-(1-isopropylpipéridin-4-yloxy)-3-méthoxyphényl]-1-(pipéridin-1-yl)prop-2-ène-1-one ;

le sel de L(+)-tartrate de

3-[4-(1-cyclobutylpipéridin-4-yloxy)-3-méthoxyphényl]-1-(pipéridin-1-yl)prop-2-ène-1-one ;

la 3-[4-(1-cyclopropylméthylpipéridin-4-yloxy)phényl]-1-(morpholin-4-yl)prop-2-ène-1-one ;

la 3-[4-(1-isobutylpipéridin-4-yloxy)phényl]-1-(morpholin-4-yl)prop-2-ène-1-one ;

la 3-[3-bromo-4-(1-isopropylpipéridin-4-yloxy)phényl]-1-(morpholin-4-yl)prop-2-ène-1-one ;

la 3-[3-bromo-4-(1-cyclobutylpipéridin-4-yloxy)phényl]-1-(morpholin-4-yl)prop-2-ène-1-one ;

la 3-[3-bromo-4-(1-isobutylpipéridin-4-yloxy)phényl]-1-(morpholin-4-yl)prop-2-ène-1-one ;

la 3-[3-bromo-4-(1-cyclopropylméthylpipéridin-4-yloxy)phényl]-1-(morpholin-4-yl)prop-2-ène-1-one ;

le sel de L(+)-tartrate de 3-[6-(1-cyclopropylméthylpipéridin-4-yloxy)pyridin-3-yl]-1-(morpholin-4-yl)prop-2-ène-1-one ;

le sel de L(+)-tartrate de 3-[6-(1-isobutylpipéridin-4-yloxy)pyridin-3-yl]-1-(morpholin-4-yl)prop-2-ène-1-one ;

la 3-[2-chloro-4-(1-cyclobutylpipéridin-4-yloxy)phényl]-1-(morpholin-4-yl)prop-2-ène-1-one ;

la 3-[2-chloro-4-(1-isopropylpipéridin-4-yloxy)phényl]-1-(morpholin-4-yl)prop-2-ène-1-one ;

la 3-[2-chloro-4-(1-cyclopropylméthylpipéridin-4-yloxy)phényl]-1-(morpholin-4-yl)prop-2-ène-1-one ;


et

la 3-[2-chloro-4-(1-isobutylpipéridin-4-yloxy)phényl]-1-(morpholin-4-yl)prop-2-ène-1-one ;

ou leurs sels pharmaceutiquement acceptables.

3. Procédé de préparation d'un composé de formule (I) selon la revendication 1, qui comprend :

(a) l'amination réductrice du composé de formule (1) avec le composé de formule (2)



en présence d'un solvant approprié et d'un agent réducteur pour former un composé de formule (I), toutes les substitutions étant telles que définies dans la revendication 1,

(b) la conversion éventuelle du composé de formule (I) en ses sels pharmaceutiquement acceptables.

4. Composition pharmaceutique comprenant un composé selon la revendication 1 et des excipients pharmaceutiquement acceptables.

5. Composition pharmaceutique selon la revendication 4, destinée à être utilisée dans le traitement des états cliniques induits par le récepteur H₃ choisis parmi les déficits cognitifs dans la schizophrénie, la narcolepsie, l'obésité, le trouble du déficit de l'attention avec hyperactivité, la douleur ou la maladie d'Alzheimer.

6. Composé selon l'une quelconque des revendications 1 ou 2 destiné à être utilisé dans le traitement de déficits cognitifs dans la schizophrénie, la narcolepsie, l'obésité, le trouble du déficit de l'attention avec hyperactivité, la douleur ou la maladie d'Alzheimer.

7. Utilisation d'un composé selon la revendication 1 dans la fabrication d'un médicament destiné au traitement de maladies associées aux récepteurs H₃ de l'histamine.

8. Utilisation d'un composé dans la fabrication d'un médicament selon la revendication 7, pour le traitement d'états cliniques choisis parmi les déficits cognitifs dans la schizophrénie, la narcolepsie, l'obésité, le trouble du déficit de l'attention avec hyperactivité, la douleur ou la maladie d'Alzheimer.

REFERENCES CITED IN THE DESCRIPTION

This list of references cited by the applicant is for the reader's convenience only. It does not form part of the European patent document. Even though great care has been taken in compiling the references, errors or omissions cannot be excluded and the EPO disclaims all liability in this regard.

Patent documents cited in the description

- WO 2007137955 A [0004]
- US 20090170869 A [0004]
- US 20100029608 A [0004]
- US 20100048580 A [0004]
- WO 2009100120 A [0004]
- WO 2009121812 A [0004]
- WO 2009135842 A [0004]


Non-patent literature cited in the description

- *British Journal of Pharmacology*, 2008, vol. 154 (6), 1166-1181 [0003]
- *Drug News Perspective*, 2010, vol. 23 (2), 99-103 [0003]
- *Indian Journal of Pharmacology*, 2001, vol. 33, 17-28 [0003]
- *Biochemical Pharmacology*, 2007, vol. 73 (8), 1215-1224 [0003]
- *Journal of Pharmacology and Experimental Therapeutics*, 2011, vol. 336 (1), 30-37 [0003]
- ENNACEUR, A. ; DELACOUR, J. A new one-trial test for neurobiological studies of memory in rats. *Behavioural data, Behav. Brain Res.*, 1988, vol. 31, 47-59 [0056]

AKRILAMID VEGYÜLETEK MINT HISZTAMIN H₃-RECEPTOR LIGANDUMOK

Szabadalmi igénypontok

1. Vegyület, amely a következő (I) általános képletű:




ahol,

R₁ jelentése egymástól függetlenül a következők közül van választva: hidrogénatom, halogénatom, alkil csoport vagy alkoxi csoport;

„A” jelentése alkil csoport, cikloalkil csoport vagy cikloalkil-alkil csoport;

„X” jelentése CH csoport vagy N atom;

„Y” jelentése CH₂ csoport, O atom vagy a következő:



vagy annak gyógyászati lag elfogadható sói.

2. Vegyület az 1. igénypont szerint, amely a következőkből álló csoportból van választva:


- 3-[4-(1-ciklobutil-piperidin-4-il-oxi)-fenil]-1-(morfolin-4-il)-prop-2-én-1-on fumarát só;
- 3-[4-(1-ciklobutil-piperidin-4-il-oxi)-fenil]-1-(piperidin-1-il)-prop-2-én-1-on hidroklorid só;
- 3-[4-(1-ciklobutil-piperidin-4-il-oxi)-fenil]-1-(1,1-dioxo-tiomorfolin-4-il)-prop-2-én-1-on hidroklorid só;
- 3-[2-(1-ciklobutil-piperidin-4-il-oxi)-piridin-5-il]-1-(piperidin-1-il)-prop-2-én-1-on L(+)-tartarát só;
- 3-[2-(1-ciklobutil-piperidin-4-il-oxi)-piridin-5-il]-1-(morfolin-4-il)-prop-2-én-1-on L(+)-tartarát só;
- 3-[2-fluor-4-(1-izopropil-piperidin-4-il-oxi)-fenil]-1-(morfolin-4-il)-prop-2-én-1-on L(+)-tartarát só;
- 3-[2-fluor-4-(1-ciklobutil-piperidin-4-il-oxi)-fenil]-1-(morfolin-4-il)-prop-2-én-1-on L(+)-tartarát só;
- 3-[4-(1-ciklobutil-piperidin-4-il-oxi)-2-metil-fenil]-1-(morfolin-4-il)-prop-2-én-1-on L(+)-tartarát só;
- 3-[4-(1-izopropil-piperidin-4-il-oxi)-2-metil-fenil]-1-(morfolin-4-il)-prop-2-én-1-on L(+)-tartarát só;
- 3-[4-(1-ciklobutil-piperidin-4-il-oxi)-fenil]-1-(morfolin-4-il)-prop-2-én-1-on L(+)-tartarát só;

- 3-[4-(1-ciklobutil-piperidin-4-il-oxi)-3-metoxi-fenil]-1-(morfolin-4-il)-prop-2-én-1-on L(+)-tartarát só;
- 3-[4-(1-ciklopropil-metil-piperidin-4-il-oxi)-3-metoxi-fenil]-1-(morfolin-4-il)-prop-2-én-1-on L(+)-tartarát só;
- 3-[4-(1-izobutil-piperidin-4-il-oxi)-3-metoxi-fenil]-1-(morfolin-4-il)-prop-2-én-1-on L(+)-tartarát só;
- 3-[4-(1-izopropil-piperidin-4-il-oxi)-3-metoxi-fenil]-1-(morfolin-4-il)-prop-2-én-1-on L(+)-tartarát só;
- 3-[4-(1-izopropil-piperidin-4-il-oxi)-3-metoxi-fenil]-1-(piperidin-1-il)-prop-2-én-1-on L(+)-tartarát só;
- 3-[4-(1-ciklobutil-piperidin-4-il-oxi)-3-metoxi-fenil]-1-(piperidin-1-il)-prop-2-én-1-on L(+)-tartarát só;
- 3-[4-(1-ciklopropil-metil-piperidin-4-il-oxi)-fenil]-1-(morfolin-4-il)-prop-2-én-1-on;
- 3-[4-(1-izobutil-piperidin-4-il-oxi)-fenil]-1-(morfolin-4-il)-prop-2-én-1-on;
- 3-[3-bróm-4-(1-izopropil-piperidin-4-il-oxi)-fenil]-1-(morfolin-4-il)-prop-2-én-1-on;
- 3-[3-bróm-4-(1-ciklobutil-piperidin-4-il-oxi)-fenil]-1-(morfolin-4-il)-prop-2-én-1-on;
- 3-[3-bróm-4-(1-izobutil-piperidin-4-il-oxi)-fenil]-1-(morfolin-4-il)-prop-2-én-1-on;
- 3-[3-bróm-4-(1-ciklopropil-metil-piperidin-4-il-oxi)-fenil]-1-(morfolin-4-il)-prop-2-én-1-on;
- 3-[6-(1-ciklopropil-metil-piperidin-4-il-oxi)-piridin-3-il]-1-(morfolin-4-il)-prop-2-én-1-on L(+)-tartarát só;
- 3-[6-(1-izobutil-piperidin-4-il-oxi)-piridin-3-il]-1-(morfolin-4-il)-prop-2-én-1-on L(+)-tartarát só;
- 3-[2-klór-4-(1-ciklobutil-piperidin-4-il-oxi)-fenil]-1-(morfolin-4-il)-prop-2-én-1-on;
- 3-[2-klór-4-(1-izopropil-piperidin-4-il-oxi)-fenil]-1-(morfolin-4-il)-prop-2-én-1-on;
- 3-[2-klór-4-(1-ciklopropil-metil-piperidin-4-il-oxi)-fenil]-1-(morfolin-4-il)-prop-2-én-1-on;
- és
- 3-[2-klór-4-(1-izobutil-piperidin-4-il-oxi)-fenil]-1-(morfolin-4-il)-prop-2-én-1-on;

vagy azok gyógyszerészetileg elfogadható sói.

3. Eljárás egy az 1. igénypont szerinti, (I) általános képletű vegyület előállítására, amely magában foglalja a következőket:

- (a) a következő (I) képletű vegyület redukatív aminálása a következő (2) képletű vegyülettel:



egy alkalmas oldószer és redukáló szer jelenlétében, hogy legyen képezve egy (I) általános képletű vegyület, ahol az összes szubsztitúció olyan, ahogyan az 1. igénypont szerint van meghatározva,

- (b) opcionálisan az (I) általános képletű vegyület átalakítása annak gyógyszerészetileg elfogadható sóivá.

4. Gyógyászati készítmény, amely tartalmaz egy az 1. igénypont szerinti vegyületet és gyógyászatiilag elfogadható segédanyagokat (excipinseket).
5. Gyógyászati készítmény a 4. igénypont szerint, klinikai állapotoknak a kezelésében történő alkalmazásra, amelyek a H_3 -receptor által vannak közvetítve, és amelyek a következők közül vannak választva: kognitív deficit a skizofrénia során, narkolepszia, elhízás (obezitás), figyelemhiányos hiperaktivitás zavar, fájdalom vagy Alzheimer-kór.
6. Vegyület az 1. igénypont vagy a 2. igénypont közül bármelyik szerint, a következőknek a kezelésében történő alkalmazásra: kognitív deficit a skizofrénia során, narkolepszia, elhízás (obezitás), figyelemhiányos hiperaktivitás zavar, fájdalom vagy Alzheimer-kór.
7. Egy az 1. igénypont szerinti vegyület alkalmazása egy gyógyszernek az előállításában, amely olyan betegségeknek a kezelésére szolgál, amelyek a Hisztamin H_3 -receptorral kapcsolatosak.
8. Egy vegyületnek az alkalmazása egy gyógyszernek az előállításában a 7. igénypont szerint, klinikai állapotoknak a kezelése céljából, amelyek a következők közül vannak választva: kognitív deficit a skizofrénia során, narkolepszia, elhízás (obezitás), figyelemhiányos hiperaktivitás zavar, fájdalom vagy Alzheimer-kór.